Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05721573 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
A Phase 2 study, sponsored by Abcuro.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
NCT05721573 is a Phase 2 study that has completed, run by Abcuro. The registered enrollment target is 272 participants.
The verdict
NCT05721573, a Phase 2 study, has completed, sponsored by Abcuro.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
Study Summary
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
Interventions
- DRUG ABC008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05721573
The ClinicalTrials.gov registry entry for NCT05721573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abcuro, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABC008 is the first listed.
NCT05721573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05721573 about?
NCT05721573 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis". A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
What is the current status of trial NCT05721573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2023-02-28. Estimated completion is 2025-11-27.
What interventions are being tested in trial NCT05721573?
The interventions under investigation include: ABC008 (DRUG).
Who is sponsoring clinical trial NCT05721573?
This trial is sponsored by Abcuro, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.